Next Article in Journal
The Gut–Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases
Next Article in Special Issue
Lycorine Carbamate Derivatives for Reversing P-glycoprotein-Mediated Multidrug Resistance in Human Colon Adenocarcinoma Cells
Previous Article in Journal
Superfast Capture of Iodine from Air, Water, and Organic Solvent by Potential Dithiocarbamate-Based Organic Polymer
Previous Article in Special Issue
Curcumin Induces Apoptosis of Chemoresistant Lung Cancer Cells via ROS-Regulated p38 MAPK Phosphorylation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 2
10.3390/ijms24021469
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression

by
Fengjing Jia
1,†,
Qun Yu
1,2,†,
Ruolei Wang
1,
Ling Zhao
1,
Fuwen Yuan
1,
Haidong Guo
1,
Yunhui Shen
2,* and
Feng He
1,*
1
Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2
School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2023, 24(2), 1469; https://doi.org/10.3390/ijms24021469
Submission received: 30 November 2022 / Revised: 16 December 2022 / Accepted: 22 December 2022 / Published: 11 January 2023
(This article belongs to the Special Issue Natural Product-Derived Compounds for Targeting Multidrug Resistance in Cancer and Microorganisms)
Browse Figures
Versions Notes

Abstract

:
Colorectal cancer (CRC) is a major health burden worldwide due to its high morbidity, mortality, and complex etiology. Fusobacterium nucleatum (Fn), a Gram-negative anaerobe found in 30% of CRC patients, promotes CRC carcinogenesis, metastasis, and chemoresistance. Effective antimicrobial treatment is an unmet need for the rising CRC burden. Antimicrobial peptides (AMPs) represent a new class of antimicrobial drugs. In our previous study, we did the structure-activity study of Jelleine-I (J-I) and identified several halogenated J-I derivatives Cl-J-I, Br-J-I, and I-J-I. To determine whether those J-I derivatives can be a new therapy for bacterial-associated CRC, here we tested the antibacterial activities of these AMPs against Fn and their effects on CRC development. We found that Br-J-I showed the highest anti-Fn activity and Br-J-I may target membrane-associated FadA for Fn membrane disruption. More importantly, Fn promoted the growth of CRC cells-derived xenograft tumors. Br-J-I suppressed Fn load, colon inflammation, and Fn-induced CRC growth. Of note, Br-J-I induced better anti-CRC effects than common antibiotic metronidazole and Br-J-I sensitized the cancer-killing effect of chemotherapy drug 5-fluorouracil. These results suggest that Br-J-I could be considered as an adjunctive agent for CRC treatment and AMPs-based combination treatment is a new strategy for CRC in the future.

1. Introduction

Colorectal cancer (CRC) is the most common malignant tumor of the digestive tract and the second leading cause of cancer-related deaths worldwide [1]. Lifestyle factors, such as prevalence of obesity, hyperlipidemia, physical inactivity, unhealthy diet, alcohol consumption, cigarette smoking, and dysbiosis, contribute to the increasing incidence and mortality of CRC [2,3]. Even though recent advances in early detection screenings and treatment options have reduced CRC mortality in developed nations, its incidence is steadily rising in both developed and developing nations [2]. The International Agency for Research on Cancer (IARC) estimates that the global burden of colorectal cancer will increase by 56% between 2020 and 2040 [1]. Furthermore, a rising incidence of early-onset CRC is emerging and poses a bigger global public health threat [4]. Early diagnosis of CRC is not very common, and most patients are diagnosed at an advanced stage. Advanced CRC is a significant cause of cancer mortality and the prognosis of advanced CRC is poor.
The ideal treatment for CRC is to achieve complete removal of the tumor and metastases, which mostly requires surgical intervention. However, most patients diagnosed with advanced state of CRC are not suitable for surgery. Chemotherapy is the most widely utilized tumor treatment and it helps to improve the disease-free survival and overall survival of patients. However, most chemotherapeutic drugs are associated with adverse effects due to their non-specific toxicities toward various types of rapidly proliferating and dividing cells in the body, such as hematopoietic stem cells in the bone marrow [5]. Furthermore, CRC often relapses after therapy and patients with relapsed/refractory CRC consistently exhibit even worse survival [6]. Therefore, there remains an unmet need for safe and effective treatments for CRC patients, especially for patients in advanced stages.
The human gut houses a large and complex micro-ecosystem, in which bacteria dominate. There are about 100 trillion microbes in the adult gut system, outnumbering human cells by 10 to 1 [7]. These microbes and the intestinal mucosal immune system constitute a complex intestinal microecology and imbalance of this microecology may lead to intestinal diseases and tumors. Pathogens often contribute to inflammation, which precedes malignant transformation, and are considered as contributors to CRC. Studies from metagenomics and next-generation sequencing found that the intestinal microecology of CRC patients exhibits dysbiosis and the flora of tumor tissues differs from those of paired normal tissues [8]. Those studies revealed that the amount of some bacteria is closely related to colorectal carcinogenesis [9]. Fusobacterium nucleatum (Fn), an anaerobic gram-negative oral commensal bacterium, was found in approximately 30% of all patients with CRC both in the intestinal microbiota but also in tumor epithelium [10,11]. Fn is extremely active in the altered intestinal microecology and is closely related to CRC initiation and progression [12,13,14]. Fn promotes CRC formation by stimulating the production of pro-inflammatory factors, such as IL-17 and TNF [11,15]. Virulence factors in Fn also contribute to colorectal carcinogenesis [13]. In addition, Fn assists CRC cells in escaping immune attack by inhibiting the cytotoxic activities of natural killer (NK) cells [16] and recruiting tumor-infiltrating myeloid cells [17]. Currently, the bacterial associated-CRC lacks effective bacterial-related drugs for CRC prevention and treatment.
The main treatments for abnormal intestinal flora are using biogenic, probiotics, fecal microbiota transplantation (FMT), and antibiotics. In the clinical study, high doses of prebiotics in a short period showed adverse effect on glucose metabolism [18]. The effects of prebiotics on the human body remain uncertain, which may be attributed to the diet habits and physical quality of subjects, as well as the dose of prebiotics intake. Probiotics and FMT are risky and may pose safety concerns [19,20]. Probiotics are beneficial to the human body by regulating intestinal flora, but they are not suitable for patients with immune deficiency and intestinal barrier dysfunction due to the potential infection and bacteremia induced by probiotics [21]. FMT may spread infectious bacteria from donors or antibiotic resistance genes from symbiotic bacteria [20]. In addition, the adverse effects of antibiotics may cause additional damage and adverse reactions in frail CRC patients [22,23]. With the extensive use of antibiotics, the emergence of a large number of antibiotic-resistant bacteria will further increase the difficulty of treatment. There is a lack of safe and effective treatment methods for intestinal bacteria. There is a huge space for the development of new drugs targeting pathogenic intestinal bacteria.
Antimicrobial peptides (AMPs) form an important component of host innate immunity in all living organisms against invading pathogens [24]. AMPs are bioactive molecules that are induced when the host is exposed to infected microorganisms to inhibit the pathogenic microorganisms. In recent years, AMPs have attracted extensive attention due to their low toxicity, good antibacterial effect, and low probability of resistance development [25,26,27,28]. In addition, peptide drugs fall in between small molecules and protein/antibody drugs with highly targeted specificity and no immunogenicity. However, low antimicrobial activity, poor metabolic stability, and short half-life usually limit the clinical applications of AMPs. Jelleine-I (J-I), first isolated from the royal jelly of honeybees, is a typical amphipathic AMP and shows broad antimicrobial spectrum [29]. We previously did the design and activity study of J-I and found that the halogenated derivatives of J-I, including Br-J-I, Cl-J-I, and I-J-I, showed potent antibacterial activity, increased proteolytic stability, and negligible cytotoxicity [30]. J-I halogenated derivatives possess great potential to be developed as a new antibacterial agent. In this study, we studied the effects of these halogenated J-I analogs on pathogenic intestinal flora, especially the cancer-promoting Fn, and the Fn-induced CRC development. We tested the antibacterial activity of these halogenated J-I analogs against Fn and the underlying mechanism. We found that, among these halogenated J-I analogs, Br-J-I showed the best antibacterial activity against Fn, and more importantly, Br-J-I effectively inhibited Fn-induced inflammation and CRC development. Br-J-I could be combined with the conventional anti-CRC drug 5-FU to improve the effects of CRC treatment.

2. Results

2.1. Br-J-I Shows Potent Antimicrobial Activity against Fn

We previously designed several new analogs of AMP J-I, aiming to search for a new J-I modifier with enhanced antimicrobial activity against some common pathogenic bacteria and we found that the halogenated derivatives of J-I, including Br-J-I, Cl-J-I, and I-J-I (Figure S1 and Table 1), showed potent antibacterial activity, increased proteolytic stability, and negligible cytotoxicity [30]. To further determine the potential clinical applications of these optimized J-I derivatives, we tested their activities on Fn, a common anaerobic gram-negative bacterium found in patients with intestinal microbiota dysbiosis, and their effects on the Fn-associated CRC. The MIC values and MBC values represent the antimicrobial activity of agents against bacteria in vitro. We first tested the antimicrobial activity against Fn of J-I and its halogenated derivatives, in which N-terminal Phe was replaced with chlorinated, brominated, and iodinated phenylalanine, respectively (Figure S1 and Table S1). Compared to J-I with an MIC of 160 μM, the MICs of Br-J-I, Cl-J-I, and I-J-I were 5 μM, 10 μM, and 10 μM, at least 10-fold increase in the anti-Fn potency (Table 2 and Figure 1). Among the halogenated derivatives, Br-J-I had the lowest MBC of 10 μM, compared with the 40 μM and 20 μM for Cl-J-I and I-J-I, respectively (Table 2). MBC of J-I was higher than 320 μM. The results showed that the halogenated J-I derivatives had better antimicrobial activity than J-I itself and Br-J-I had the best antimicrobial activity.

2.2. Br-J-I Induces Membrane Disruption of Fn to Inhibit Fn

To understand how Br-J-I exerts bactericidal effect, we first tested whether Br-J-I induces H2O2 formation, which is a common mechanism contributing to the death of bacteria. Compared with positive control that kills bacteria by H2O2, Br-J-I did not alter intracellular level of H2O2 in Fn (Figure 2A). Then, we measured membrane integrity of Fn after treatment with Br-J-I, which is a common bacterial disruption mechanism for AMPs [31,32,33]. NPN is a hydrophobic fluorescent probe and its fluorescence intensity is weak in a hydrophilic environment, unless in a hydrophobic phospholipid membrane environment. NPN does not normally go to the inside of cells, because it cannot penetrate the cell outer membrane. When the outer membrane is damaged, NPN can access the cellular phospholipid membrane and fluoresce strongly. In contrast to background control fluorescence, strong NPN fluorescence was detected 1 min after Br-J-I addition and reached equilibrium (Figure 2B). Br-J-I induced increase of NPN fluorescence in a dose-dependent manner. To further detect the effect of Br-J-I on the membrane integrity, propidium iodide (PI) was used to stain the DNA of Fn in the presence of increasing concentrations Br-J-I and quantitated by flow cytometry. PI is membrane impermeable unless cell membranes are damaged. When PI binds to DNA, it produces strong red fluorescence. Br-J-I treatment significantly increased red fluorescent PI of Fn (Figure 2C). In addition, Fn was co-stained with lipophilic membrane-selective fluorescent dye FM4–64 and membrane permeable nucleic acid dye AO in the absence or presence of Br-J-I. In the absence of Br-J-I, FM4–64 was co-stained with AO (Figure 2D,E). When Br-J-I was present, fluorescence of FM4–64-stained Fn membrane was decreased (Figure 2D,E), thereby loss of co-staining of FM4–64 with AO, indicating that Br-J-I induced disruption of membrane integrity. The result suggested Br-J-I kills Fn by disrupting its membrane integrity. To further understand the mechanism of Br-J-I induced membrane disruption, we subsequently did molecular docking analysis between Br-J-I and structurally available bacterial membrane proteins with potential oligomerization domains. We found that Fusobacterium adhesin A (FadA), as the unique protein of Fusobacterium, is a potential binding target of Br-J-I. Br-J-I binds to the oligomerization domain of FadA with the binding free energy of −3.8 kcal/mol, and interfacial residues between them form three hydrogen bonds: one between S5 of Br-J-I and Y18 of FadA, the second one between K2 of Br-J-I and N111 of FadA, and the third one between H7 carboxyamide group of Br-J-I and E25 of FadA (Figure 3A). Br-J-I fits in an amphipathic groove of FadA with hydrophobic surface in the center and negative charged surface on the edge of groove (Figure 3B). FomA is a major outer-membrane protein of Fn [34] and AlphaFold prediction showed that FomA is structurally similar to multi-stranded anti-parallel beta-barrel containing a pore that aids the diffusion of small hydrophilic molecules across the outer membrane of Gram-negative bacteria [35,36]. Molecular docking revealed that Br-J-I interacts with FomA with the binding free energy of −6.6 kcal/mol (Figure S2). FomA has heat-modifiable oligomeric and conformational properties [34] and binding of Br-J-I to FomA may contribute to FomA stability and membrane permeability for Fn demise. FadA locates in the outer membrane of Fn and the molecular docking results suggest that Br-J-I likely targets FadA oligomerization motif and induces FadA oligomerization within membrane to permeabilize the membrane.

2.3. Br-J-I Exhibits Little Cytotoxicity to Colon Epithelial Cells and CRC Cells

Since Br-J-I displays potent anti-Fn activity, its cytotoxicity toward mammalian cells is one of the important factors that cannot be ignored. We used MTT assay to determine the cytotoxicity of Br-J-I to colon epithelial cells and colon cancer cells. As shown in Figure 4A–E and Figure S3, after 72 h incubation, Br-J-I, with the concentration up to 16 × MIC, did not show any significant observable effect on the viability of colon cancer cells HCT116, Lovo, HT29, MC38, and human colon epithelial cells NCM460. The results showed that Br-J-I had negligible cytotoxicity to human colon epithelial cells and colon cancer cells. This presents an advantage: that we can apply a dosage that specifically kills Fn, but with no cytotoxicity to mammalian cells.

2.4. Br-J-I Suppresses the Tumor-Promoting Effect of Fn

The effect of Br-J-I on cell proliferation of human colon cancer cells with Fn was determined by cell counting. HCT116 cells were co-cultured with Fn in the absence or presence of Br-J-I and the cell numbers were counted at 24 h, 48 h, and 72 h of incubation. Fn alone increased the cell proliferation of HCT116 cells and the cell numbers were dramatically increased from 24 h to 72 h (Figure 5A–C). When Br-J-I was present at 2.5 μM, 5 μM, and 10 μM, the Fn increased cell proliferation of HCT116 cells was significantly suppressed, to a level similar to that of the control group without Fn (Figure 5A–C). Of note, Br-J-I alone did not affect cell proliferation even at higher concentrations, as shown in Figure 4A. These results indicate that Fn enhanced the HCT116 proliferation and this effect was suppressed by Br-J-I.

2.5. Br-J-I Inhibits the Growth of CRC Induced by Intratumoral Fn in Mice Engrafted with HCT116

To detect the effects of Br-J-I on the CRC tumor growth induced by Fn in vivo, CRC cells HCT116 were engrafted into mice and when tumors were formed, Fn was intratumorally colonized and different doses of Br-J-I were intraperitoneally administrated into mice every three days. Compared with the control group, Fn increased the CRC growth rate, evidenced by 100% increases in tumor size and tumor weight (Figure 6A,B). Both Br-J-I (10 mg/kg) and positive control metronidazole (MET, 40 mg/kg) suppressed the tumor-promoting effects of Fn and the tumor-inhibitory role of Br-J-I was better than that of MET (Figure 6A,B). In agreement with this, tumor proliferation marker Ki-67 was stained more in the Fn-treated CRC xenograft tumors, less in the group of Fn plus Br-J-I or group of Fn plus MET (Figure 6C). These results indicated that Br-J-I effectively inhibits the CRC tumor-promoting effect of Fn.
Fn load of the tumor tissues of CRC mice with Fn colonization was quantitated to further analyze whether Br-J-I suppresses the CRC growth by directly blocking Fn in tumors. As shown in Figure 6D, Fn-specific RNA was not detected in tumor tissues of CRC mice without Fn inoculation. After Fn inoculation, Fn-specific RNA in tumor tissues of CRC mice was dramatically increased. When Br-J-I was administrated, Fn-specific RNA was significantly reduced in tumor tissues of CRC mice with Fn colonization, similar to metronidazole (MET). In addition, Br-J-I inhibited the expression of the key Fn gene FadA within CRC xenografts (Figure 6E). These results suggest that Br-J-I suppresses the increased growth of CRC tumors enhanced by Fn.

2.6. Br-J-I Inhibits Fn-Induced Inflammation

Bacteria-induced inflammation is closely related to CRC progression [37,38]. To further examine the inhibition of Fn by Br-J-I, H&E staining was used to determine the effect of Br-J-I on the Fn-induced inflammation in vivo. Fn administration altered colon histology and damaged the gut barrier (Figure 7A). When Br-J-I was administrated, the inflammation of colon tissues in CRC mice xenografts with Fn colonization was reduced compared to the Fn group (Figure 7A). To further verify the effect of Br-J-I on the inhibition of Fn-induced inflammation, the expression of key inflammatory cytokines TNF-α and IL-1β in the tumors and colon tissues of CRC mice xenografts was quantitated. As shown in Figure 7B–E, the expression of genes encoding the proinflammatory cytokines TNF-α and IL-1β in tumors and colon tissues were dramatically increased after Fn inoculation. Br-J-I decreased the expression of Tnf and IL1b mRNA in both tumors and colons of CRC mice with Fn colonization. The Br-J-I exhibited more Tnf inhibitory effect than MET, while Br-J-I and MET showed similar inhibitory effects on IL1b. These results indicated that Br-J-I inhibits Fn-associated CRC growth by directly suppressing Fn and Fn-induced inflammation.

2.7. Br-J-I Improves Intestinal Mucosa Tight Junction (TJ) in HCT116 Cell-Engrafted Mice with Intratumoral Fn Colonization

Intestinal mucosa plays an important role in the absorption of nutrients and drugs. The intestinal mucosal barrier is closely related to the TJ, including the expression of key TJ proteins Claudin and ZO-1 [39]. To further test whether Br-J-I affects intestinal mucosal barrier, the effect of Br-J-I on the expression of TJ proteins Claudin and ZO-1 was detected. After inoculation with Fn, the expression of mRNAs encoding TJ proteins Claudin and ZO-1 were reduced significantly (Figure 8A,B). Br-J-I administration rescued the expression of Claudin and Zo-1mRNAs in intestinal tissue of CRC mice within Fn colonization, to a level similar to the control without Fn, indicating the improvement of intestinal barrier by Br-J-I. The results suggest that Br-J-I enhances the intestinal mucosal barrier by up-regulating the expression of key TJ proteins. Compared with MET, Br-J-I exhibited better anti-Fn effects in vivo and improved the intestinal mucosal barrier.

2.8. Br-J-I Synergizes with 5-FU to Exert the Antitumor Effect

Br-J-I does not act directly on the tumor cells, it inhibits the CRC progression induced by Fn and Fn-associated cancer-promoting inflammation. The 5-FU-based chemotherapy is a common treatment for CRC. However, clinical outcomes of 5-FU for CRC patients need to be improved, due to the emergence of relapse and refractory in CRC patients [40]. The effect of Br-J-I combined with 5-FU chemotherapy on the antitumor activity against CRC cells co-cultured with Fn was detected. At the concentration of 5 μM, 5-FU exhibited little cytotoxicity against HCT116 cells (Figure 9A,B). In line with Figure 5A–C, Br-J-I alone inhibited the tumor proliferation induced by Fn, shown as about 20% decrease in viability by MTT assay at 10 μM. When combined with Br-J-I, the cell proliferation of HCT116 cells was further reduced by about 40%. The Q values of the combination of Br-J-I (20 μM) with 5-FU (5 μM) were over 1.15, indicating a strong anti-tumor synergistic effect. The results suggested that the combination of Br-J-I and 5-FU exerts a better antitumor effect.

3. Discussion

At present, the clinical treatment of CRC mainly focuses on the tumors or the host itself, and the efficacy of the treatments is far from satisfactory. The existing treatment option cannot meet the needs of various CRC patients. Fn has been found to be abnormally increased in tumor tissues of CRC patients, which is one of the driving forces for the initiation and development of CRC [10,41,42]. However, safe and efficient treatment options for intestinal bacteria are very scarce, and the development of novel agents targeting intestinal bacteria is in urgent need.
AMPs are a kind of bioactive peptide produced in organisms, widely existing in insects, plants, and animals. As an important part of the innate immune defense, AMPs have the potential to be developed as new antimicrobials [43]. AMPs have a broad spectrum of antimicrobial activity and they usually kill microbes by disrupting cell membranes, through which they are less likely to develop resistance. AMPs often have low cytotoxicity to mammalian cells. In addition, AMPs have potent antitumor effects [44]. Due to these advantages, including potent antimicrobial activity, low toxicity, and difficulty in developing resistance, AMPs have become one of the hot spots in the research and development of novel antimicrobial agents.
In this study, AMPs were used to study the effects on the growth of CRC by regulating intestinal bacteria. The clinical studies have shown that the intestinal flora abnormally increased in CRC patients are mainly Gram-negative bacteria [11,12,14]. Our previous studies showed that AMP J-I derivatives, Br-J-I, Cl-J-I, and I-J-I showed potent antibacterial activity against Gram-negative bacteria [30]. In addition, these peptide analogs have very low cytotoxicity and good selectivity. In this study, the antibacterial activities of these peptide analogs against Fn were detected. The results showed that Br-J-I had the best antibacterial activity among these J-I derivatives. Subsequently, the antimicrobial mechanism of Br-J-I was studied. By studying membrane integrity, we found that the fluorescence of membrane-selective dye FM4–64 was decreased, indicating that Br-J-I disrupted the integrity of the bacterial cell membrane. Therefore, after Br-J-I treatment, extracellular fluorescent probe, such as PI, can permeate Fn and bind with DNA to produce strong fluorescence. The results showed that Br-J-I killed Fn by inducing the cell membrane disruption, which was consistent with the images of scanning electron microscopy of Br-J-I and other J-I derivatives against Escherichia coli (E. coli) in our previous study [30]. Electron microscopy revealed that addition of Br-J-I induced the formation of protrusions in the bacterial membrane and, eventually, disassembled the bacterial membrane [30]. In in vitro assay, we did not see the oligomerization property of Br-J-I and Br-J-I is not likely a transmembrane helix due to its short length and its amino acids distribution. Br-J-I could target bacterial membrane proteins and upon the binding of Br-J-I, the confirmational changes and oligomerization of complex could mediate the formation of bacterial membrane protrusions. FadA locates in the outer membrane of bacteria, which is a potential binding target of Br-J-I by molecular docking analysis. Br-J-I might target FadA oligomerization motif and induce FadA oligomerization within the membrane to permeabilize the membrane. Moreover, recent studies have proved that Gram-negative bacteria such as Fn and E. coli are closely associated with the initiation and development of CRC [14]. Our previous studies showed that Br-J-I exhibited potent antibacterial activity against E. coli [30]. High cytotoxicity is one of the factors limiting the widespread application of antibacterial agents. Although some antibiotics have excellent antibacterial activity, their high toxicity to host cells is unsuitable for frail and vulnerable CRC patients. In addition, the cytotoxicity of Br-J-I on human colon epithelial cells, human colorectal cancer cells, and murine colon cancer cell lines was minimal, and no significant cytotoxicity was found even at high doses (>8 MIC). These results suggest that Br-J-I will be tailor-made for CRC.
Fn promoted the proliferation of CRC cells, while the treatment of Br-J-I significantly rescued the proliferation of CRC cells by inhibiting Fn. The in vivo studies verified that Fn promoted the growth of CRC tumors and when Br-J-I was administrated, it significantly hindered the growth of CRC tumors by inhibiting Fn. We further quantified Fn load in the tumor tissue and showed that Br-J-I significantly reduced Fn load in the xenograft tumors in mice within Fn colonization. Consistently, the expression of FadA in tumors and colons was also reduced by Br-J-I. These results indicated that Br-J-I inhibited the Fn-induced growth of CRC tumors by directly blocking Fn. Moreover, our results showed that Br-J-I blocked the production of proinflammatory cytokines induced by Fn. This has important implications for the treatment of CRC, because CRC growth can be inhibited by suppressing the proinflammatory cytokines [38,45,46].
Br-J-I has potent antimicrobial activity and no cytotoxicity to CRC itself, and it significantly inhibits the growth of CRC promoted by Fn, suggesting that Br-J-I counteracts the adverse effects of Fn on CRC through its antimicrobial activity against Fn. The results indicated that the effect of Br-J-I on CRC tumors was mainly due to an indirect effect. 5-FU-based chemotherapy is a common treatment for CRC. Resistance to 5-FU often also emerges and clinical outcomes of 5-FU for CRC treatment is urgently needed for improvement [47]. At the concentration of 5 μM, 5-FU exhibited little cytotoxicity against HCT116 cells. After combination with Br-J-I, the cell viability of HCT116 cells was dramatically reduced by more than 40%. This suggests that Br-J-I sensitizes the cytotoxicity of 5-FU and Br-J-I synergizes with 5-FU to exert a better antitumor effect. Therefore, Br-J-I could be an ideal adjunctive therapy for CRC.

4. Materials and Methods

4.1. Synthesis and Purification of AMPs

AMPs were synthesized by a stepwise solid-phase method on rink amide 4-methyl-benzhydryl amine (MBHA) resin by N-9-fluorenylmethoxycarbonyl (Fmoc) chemistry, as described [48]. AMPs were purified by reverse phase high-performance liquid chromatography (RP-HPLC) (Waters 600, Milford, MA, USA) and gradient elution by 20–80% CH3CN/H2O with μBondapak C18 19 mm by 300 mm column [30]. The purity of these peptides is more than 95% determined by NMR.

4.2. Minimum Inhibitory Concentration (MIC) Assay

MICs of J-I and its halogenated derivatives against Fusobacterium nucleatum (Fn) (ATCC 25586) were determined by the Clinical and Laboratory Standards Institute microdilution method [30]. Fn was cultured in brain heart infusion broth (BD Difco, Cockeysville, MD, USA) at 37 °C under the anaerobic workstation (Don Whitley Scientific, Bingley, UK). Bacteria were cultured to logarithmic growth phase and adjusted to the inoculum size of 3 × 108 colony-forming units (CFU)/mL. Bacterial inoculum was incubated with various concentrations of AMPs or positive control metronidazole (MET) at 37 °C for 24 h. Each experiment was independently replicated at least three times.

4.3. Minimum Bactericidal Concentration (MBC) Assay

MBC of J-I and its halogenated derivatives were determined based on their MIC. The mixture with peptide analogs at different concentrations above the MIC was added to agar plates and then incubated at 37 °C. After 24 h, the number of CFU was observed [30]. The concentration that decreased the viability of Fn by ≥99.9% was defined as MBC of J-I and its halogenated derivatives.

4.4. Outer Membrane (OM) Permeability

The effect of Br-J-I on the OM permeability of Fn was determined by hydrophobic fluorescent probe N-Phenyl-1-naphthylamine (NPN, Aladdin, Shanghai, China) as previously described [30]. Fn was washed and suspended with PBS. The bacterial inoculum was adjusted to the OD 600 nm (OD600) of 0.5 ± 0.02 and divided into two groups: (1) peptides groups (100 μL Fn solution + 50 μL peptide+ 50 μL NPN); (2) Control group (100 μL Fn solution + 50 μL PBS + 50 μL NPN). The concentration of peptides is 1 × MIC to 8 × MIC. NPN fluorescence was continuously monitored for 13 min using a multifunctional microplate reader (Molecular Devices, Shanghai, China) with the excitation and emission wavelength of 350 nm and 420 nm, respectively.

4.5. Flow Cytometric Analysis

Fn was washed and suspended in PBS. The OD600 of bacterial inoculum was adjusted to 0.4 and treated with Br-J-I with the concentrations from 1 × MIC to 4 × MIC at 37 °C. After 5 min, the mixture was washed and suspended in PBS, followed by addition of 1 μL propidium iodide (PI, 1 mg/mL) for 15 min [49]. The effect of AMPs on the membrane permeability of Fn was conducted by using flow cytometer (Becton Dickinson and Company, Franklin Lakes, NJ, USA).

4.6. Laser Scanning Confocal Microscopy (LSCM)

Fn was washed and suspended in PBS with an OD600 of 0.4. The bacterial solution was treated with Br-J-I at the concentrations from 1 × MIC to 4 × MIC at 37 °C. After 1 h, the mixture was washed and resuspended in PBS containing 1 μL membrane-selective red fluorescent dye FM4-64 (1 μg/mL) and cell-permeant nucleic acid binding dye acridine orange (AO, 1 μg/mL) to stain the nucleic acids for 15 min. The fluorescence imaging was conducted by LSCM (Leica TCS SP8, Nussloch, Germany).

4.7. Binding Mode Prediction

The sequence and structure of the peptide was drawn by ChemDraw software to obtain the 2D structure of the peptide and the 2D structure of the peptide was then imported into Chem3D software to transform it into a 3D structure of the peptide according to the default parameters of the software [50]. The 3D structure of the peptide was used for the molecular docking analysis. The binding model of Br-J-I with Fn was predicted as formerly described [51]. The crystal structures of key bacterial proteins FadA (PDB: 3ETW) were downloaded from the Protein Data Bank. The structures of FomA were downloaded from AlphaFold prediction database with the code AF-Q47903 [36,52]. Molecular docking was performed by Vina docking software v.1.1.2. (http://vina.scripps.edu/). The interaction between ligand and receptor was determined by PyMOL software v1.7.2.1 (http://www.pymol.org/2/) to obtain information on binding energy and hydrogen bond.

4.8. Cytotoxicity

The cytotoxicity of Br-J-I was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Beyotime, Jiangsu, China), as previously described [53]. Human CRC cell lines HCT116 (RRID: CVCL_0291), HT29 (RRID: CVCL_A8EZ), LoVo (RRID: CVCL_0399), and human colon epithelial cell line NCM460 (RRID: CVCL_0460) were purchased from the Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences. Murine colon cancer cell line MC38 was purchased from the Chinese Academy of Medical Sciences. The cells were cultured in Dulbecco’s modified Eagle medium (Gibco, Grand Island, NY, USA) supplemented with 10% Fetal Bovine Serum (Gibco, Grand Island, NY, USA), penicillin, and streptomycin at 37 °C with 5% CO2. 1 × 104 cells were seeded per well in a 96-well plate and cultured overnight before addition of various concentrations of Br-J-I. After 72 h incubation with the AMPs, 20 μL MTT solution (5 mg/mL) was added to each well and incubated at 37 °C for 4 h [54]. The supernatant was discarded, and 150 μL dimethyl sulphoxide was added. The absorbance at 570 nm was detected by a microplate reader (Molecular Devices, Shanghai, China). The experiments were repeated 3 times. All human cell lines have been authenticated using STR (or SNP) profiling within the last three years. All experiments were performed with mycoplasma-free cells. All cell lines used was provided from American Type Culture Coll.

4.9. Effect of Br-J-I on Cell Proliferation

The Effect of Br-J-I on cell proliferation of colorectal cancer co-cultured with Fn was determined as previously described [55,56]. Human colorectal cancer cell lines HCT116 were seeded in a 24-well plate at a density of 1 × 104 cells per well. Cells were incubated with Fn (multiplicity of infection of 1000) in the presence and absence of various concentrations of Br-J-I. Cell counts for each group were conducted at 24 h, 48 h, and 72 h by Countstar cell counter (ALIT, Shanghai, China). Each experiment was independently replicated at least three times.

4.10. Effect of Br-J-I on the Growth of Murine CRC with Fn Colonization

The murine CRC with bacterial colonization was conducted as previously described [41,57]. Mouse experiments were performed under the National Guidelines for Animal Usage in Research of China and the guideline of the Ethics Committee of Shanghai University of Traditional Chinese Medicine with the approved protocol PZSHUTCM220711010. All NU/NU nude mice were purchased from the Shanghai Slac laboratory animals center. Human colorectal cancer cell HCT116 was subcutaneously injected into the right axilla of 4-week-old nude mice (1 × 107 cells /100 μL PBS of each mouse) to establish the CRC xenograft model. Mice were randomly divided into 4 groups: (a) Saline as a control group; (b) Fn group; (c) Br-J-I (10 mg/kg) +Fn; (d) metronidazole (MET, 40 mg/kg positive group) +Fn. Nine days after HCT116 inoculation, Fn or vehicle control was intratumorally injected into each mouse every 3 days for 18 days. In addition, on the same day, mice were intraperitoneally administrated with Br-J-I or MET for the selected group every 3 days for 18 days. Tumor volume = (A × B2) /2, where A and B are the length and width and measured every 3 days. After the last administration, the mice were sacrificed for the collection of tumors and colon tissues. Tumors and colon tissues were fixed in 10% formalin, and then embedded in paraffin. Tumor sections were stained with Ki-67 monoclonal antibody (1:200, Servicebio, Wuhan, China) and colon tissues were stained with hematoxylin–eosin (H&E) (Solarbio, Beijing, China).

4.11. Quantification of Fn Load in the Tumors and the Expression of the Proinflammatory Cytokines in Tumors and Colon Tissues

Quantitative real-time polymerase chain reaction (qPCR) was used to quantitate Fn load in the tumors [10,17] and the expression of the proinflammatory cytokines in tumors and colon tissues as previously described [41,58,59]. Total RNAs were extracted from CRC tumors or colons using Trizol reagent (Beyotime, Shanghai, China) according to the manufacturer’s protocol. Hifair®®IIISuperMix Plus (Yeasen, Shanghai, China) and Hieff®® qPCR SYBR Green Master Mix (Yeasen, Shanghai, China) were used to do the reverse transcription and qPCR, respectively, according to the manufacturer’s instructions. Relative mRNA expression of different groups was calculated by 2(−ΔΔCT) method. The sequences of primers were listed in Table S1.

4.12. Analysis of Intestinal Permeability of Murine CRC

The effect of Br-J-I and MET on the expression of tight junction proteins Zona occludens protein 1 (ZO-1) and Claudin in the intestinal tissue of CRC-engrafted mice inoculated with Fn were analyzed by qPCR as described above.

4.13. Effect of Br-J-I Combined with 5-Fluorouracil

Cell viability was measured by MTT assay. HCT116 cells (5000 cells/well) were seeded in a 96-well plate in the presence or absence of Fn (multiplicity of infection of 1000) and treated with different concentrations of Br-J-I and 5-fluorouracil (FU) (5 μM) for 48 h. The medium was carefully discarded, and RPMI1640 medium and 20 μL MTT solution (5 mg/mL) were added to incubate for 4 h. The medium was discarded and replaced with 150 μL dimethyl sulphoxide (DMSO). The absorbance was measured at 570 nm by a microplate reader (Molecular Devices, Shanghai, China). The synergistic effect of Br-J-I and 5-FU against HCT116 cells was estimated by Q value [60]. The Q value was calculated by the equation: Q = E (A + B)/E(A) + E(B) − E(A) × E(B) [61], where E(A + B) means the tumor growth inhibition rates of the combination of Br-J-I and 5-FU, E(A) and E(B) represent the tumor growth inhibition rates of Br-J-I and 5-FU, respectively. Q < 0.85 suggests an antagonistic effect of Br-J-I and 5-FU. 0.85 ≤ Q < 1.15 suggests an additive effect of Br-J-I and 5-FU. Q ≥ 1.15 suggests a synergistic effect of Br-J-I with 5-FU.

4.14. Statistical Analyses

Graphpad prism 8.0.2 software was used for data analysis and graphing. Statistical significance was evaluated by one-way analysis of variance (ANOVA with Dunnett’s post-hoc analysis). All values are expressed as mean ± SEM, and values of p < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, compared with Fn group. #p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001, compared with the NC group.

5. Conclusions

In summary, the optimized AMP Br-J-I, designed by us, exhibits potent antibacterial activity against Fn with negligible cytotoxicity. Br-J-I effectively inhibited Fn-induced tumor-promoting effect of CRC and inflammation by directly killing Fn, which has the potential to become a novel therapy for regulating intestinal bacterial dysbiosis and an adjunct therapy for CRC. Several intestinal bacteria, including Fn, are abnormally active in CRC patients, posing a great risk of colorectal carcinogenesis, cancer metastasis, and chemoresistance. However, safe and efficient treatment options for intestinal bacteria are very scarce in fragile CRC patients. This study provides a novel approach for the clinical treatment of CRC, in which AMPs can be used as adjuvant therapy to eliminate the adverse effects of pathogenic intestinal bacteria on CRC. In addition, Br-J-I synergizes with 5-FU to exert the antitumor effect, proving that Br-J-I as adjunctive therapy would further enhance the chemotherapy efficacy of CRC. We hope that this study will provide a new direction for the future development of candidates for adjunctive therapy for CRC.

Supplementary Materials

The supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24021469/s1.

Author Contributions

F.J. and Q.Y. conceived the project, performed the experiments, analyzed the data, and wrote the original draft. R.W. performed the experiments and analyzed the data. L.Z. and F.Y. provided the materials and reviewed the manuscript. H.G. and Y.S. provided the materials, provided editorial advice, and supervised the study. F.H. designed the project, supervised the study, and edited manuscript. All authors discussed and approved the manuscript.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No. 82003641 and No. 82172947).

Institutional Review Board Statement

All mouse experiments were performed according to the guideline of the Ethics Committee of Shanghai University of Traditional Chinese Medicine and the National Guidelines for Animal Usage in Research (China) (Protocol No.: PZSHUTCM220627053). No humans were participated in this project.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

There is no conflict of interest for all authors.

Abbreviations

AO: Acridine Orange; Antimicrobial peptides (AMPs); CFU: colony forming units; CRC: Colorectal cancer; CT: cycle threshold; DMSO: dimethyl sulfoxide; FadA: Fusobacterium adhesin A; 5-FU: 5-Fluorouracil; Fn: Fusobacterium nucleatum; H&E: hematoxylin–eosin; IL-1β: interleukin-1β; Jelleine-I (J-I); MBC: Minimum bactericidal concentration; MET: Metronidazole; MIC: Minimum inhibition concentration; MOI: multiplicity of infection; MSI: microsatellite instability; NPN: N-Phenyl-1-naphthylamine; PI: Propidium Iodide; qPCR: quantitative polymerase chain reaction; TNF-α: tumor necrosis factor α; ZO-1: Zonula occludens protein 1.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  2. Rawla, P.; Sunkara, T.; Barsouk, A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz. Gastroenterol. 2019, 14, 89–103. [Google Scholar] [CrossRef] [PubMed]
  3. Kim, J.; He, F.; Karin, M. From Liver Fat to Cancer: Perils of the Western Diet. Cancers 2021, 13, 1095. [Google Scholar] [CrossRef] [PubMed]
  4. Akimoto, N.; Ugai, T.; Zhong, R.; Hamada, T.; Fujiyoshi, K.; Giannakis, M.; Wu, K.; Cao, Y.; Ng, K.; Ogino, S. Rising incidence of early-onset colorectal cancer—A call to action. Nat. Rev. Clin. Oncol. 2021, 18, 230–243. [Google Scholar] [CrossRef] [PubMed]
  5. Wang, Y.; Probin, V.; Zhou, D. Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. Curr. Cancer Ther. Rev. 2006, 2, 271–279. [Google Scholar] [CrossRef] [Green Version]
  6. Chu, D.; Zhang, Z.; Li, Y.; Wu, L.; Zhang, J.; Wang, W.; Zhang, J. Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2. Mol. Cancer Ther. 2011, 10, 47–56. [Google Scholar] [CrossRef] [Green Version]
  7. Gomes, A.C.; Hoffmann, C.; Mota, J.F. The human gut microbiota: Metabolism and perspective in obesity. Gut Microbes 2018, 9, 308–325. [Google Scholar] [CrossRef] [Green Version]
  8. Cheng, Y.; Ling, Z.; Li, L. The Intestinal Microbiota and Colorectal Cancer. Front. Immunol. 2020, 11, 615056. [Google Scholar] [CrossRef]
  9. Huh, J.W.; Roh, T.Y. Opportunistic detection of Fusobacterium nucleatum as a marker for the early gut microbial dysbiosis. BMC Microbiol. 2020, 20, 208. [Google Scholar] [CrossRef]
  10. Kostic, A.D.; Gevers, D.; Pedamallu, C.S.; Michaud, M.; Duke, F.; Earl, A.M.; Ojesina, A.I.; Jung, J.; Bass, A.J.; Tabernero, J.; et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012, 22, 292–298. [Google Scholar] [CrossRef]
  11. Mima, K.; Nishihara, R.; Qian, Z.R.; Cao, Y.; Sukawa, Y.; Nowak, J.A.; Yang, J.; Dou, R.; Masugi, Y.; Song, M.; et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016, 65, 1973–1980. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Haruki, K.; Kosumi, K.; Hamada, T.; Twombly, T.S.; Vayrynen, J.P.; Kim, S.A.; Masugi, Y.; Qian, Z.R.; Mima, K.; Baba, Y.; et al. Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer. J. Pathol. 2020, 250, 397–408. [Google Scholar] [CrossRef] [PubMed]
  13. Chen, Y.; Chen, Y.; Zhang, J.; Cao, P.; Su, W.; Deng, Y.; Zhan, N.; Fu, X.; Huang, Y.; Dong, W. Fusobacterium nucleatum Promotes Metastasis in Colorectal Cancer by Activating Autophagy Signaling via the Upregulation of CARD3 Expression. Theranostics 2020, 10, 323–339. [Google Scholar] [CrossRef] [PubMed]
  14. Marmol, I.; Sanchez-de-Diego, C.; Pradilla Dieste, A.; Cerrada, E.; Rodriguez Yoldi, M.J. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int. J. Mol. Sci. 2017, 18, 197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Cochrane, K.; Robinson, A.V.; Holt, R.A.; Allen-Vercoe, E. A survey of Fusobacterium nucleatum genes modulated by host cell infection. Microb Genom. 2020, 6, e000300. [Google Scholar] [CrossRef] [PubMed]
  16. Hashemi Goradel, N.; Heidarzadeh, S.; Jahangiri, S.; Farhood, B.; Mortezaee, K.; Khanlarkhani, N.; Negahdari, B. Fusobacterium nucleatum and colorectal cancer: A mechanistic overview. J. Cell Physiol. 2019, 234, 2337–2344. [Google Scholar] [CrossRef]
  17. Kostic, A.D.; Chun, E.; Robertson, L.; Glickman, J.N.; Gallini, C.A.; Michaud, M.; Clancy, T.E.; Chung, D.C.; Lochhead, P.; Hold, G.L.; et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013, 14, 207–215. [Google Scholar] [CrossRef] [Green Version]
  18. Liu, F.; Li, P.; Chen, M.; Luo, Y.; Prabhakar, M.; Zheng, H.; He, Y.; Qi, Q.; Long, H.; Zhang, Y.; et al. Fructooligosaccharide (FOS) and Galactooligosaccharide (GOS) Increase Bifidobacterium but Reduce Butyrate Producing Bacteria with Adverse Glycemic Metabolism in healthy young population. Sci. Rep. 2017, 7, 11789. [Google Scholar] [CrossRef] [Green Version]
  19. Shridhar, P.B.; Amachawadi, R.G.; Tokach, M.; Patel, I.; Gangiredla, J.; Mammel, M.; Nagaraja, T.G. Whole genome sequence analyses-based assessment of virulence potential and antimicrobial susceptibilities and resistance of Enterococcus faecium strains isolated from commercial swine and cattle probiotic products. J. Anim. Sci. 2022, 100, skac030. [Google Scholar] [CrossRef]
  20. Hill, C. Balancing the risks and rewards of live biotherapeutics. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 133–134. [Google Scholar] [CrossRef]
  21. Rautio, M.; Jousimies-Somer, H.; Kauma, H.; Pietarinen, I.; Saxelin, M.; Tynkkynen, S.; Koskela, M. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin. Infect. Dis. 1999, 28, 1159–1160. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Settle, C.D.; Wilcox, M.H. Review article: Antibiotic-induced Clostridium difficile infection. Aliment Pharmacol. Ther. 1996, 10, 835–841. [Google Scholar] [CrossRef] [PubMed]
  23. Gleckman, R.A.; Borrego, F. Adverse reactions to antibiotics. Clues for recognizing, understanding, and avoiding them. Postgrad Med. 1997, 101, 97–98, 101–104, 107–108. [Google Scholar] [CrossRef]
  24. Reddy, K.V.; Yedery, R.D.; Aranha, C. Antimicrobial peptides: Premises and promises. Int. J. Antimicrob. Agents 2004, 24, 536–547. [Google Scholar] [CrossRef] [PubMed]
  25. Tanhaieian, A.; Sekhavati, M.H.; Ahmadi, F.S.; Mamarabadi, M. Heterologous expression of a broad-spectrum chimeric antimicrobial peptide in Lactococcus lactis: Its safety and molecular modeling evaluation. Microb. Pathog. 2018, 125, 51–59. [Google Scholar] [CrossRef]
  26. Tanhaeian, A.; Mirzaii, M.; Pirkhezranian, Z.; Sekhavati, M.H. Generation of an engineered food-grade Lactococcus lactis strain for production of an antimicrobial peptide: In vitro and in silico evaluation. BMC Biotechnol. 2020, 20, 19. [Google Scholar] [CrossRef] [Green Version]
  27. Pirkhezranian, Z.; Tanhaeian, A.; Mirzaii, M.; Sekhavati, M.H. Expression of Enterocin-P in HEK Platform: Evaluation of Its Cytotoxic Effects on Cancer Cell Lines and Its Potency to Interact with Cell-Surface Glycosaminoglycan by Molecular Modeling. Int. J. Pept. Res. Ther. 2020, 26, 1503–1512. [Google Scholar] [CrossRef]
  28. Tahmoorespur, M.; Azghandi, M.; Javadmanesh, A.; Meshkat, Z.; Sekhavati, M.H. A Novel Chimeric Anti-HCV Peptide Derived from Camel Lactoferrin and Molecular Level Insight on Its Interaction with E2. Int. J. Pept. Res. Ther. 2020, 26, 1593–1605. [Google Scholar] [CrossRef]
  29. Fontana, R.; Mendes, M.A.; de Souza, B.M.; Konno, K.; Cesar, L.M.; Malaspina, O.; Palma, M.S. Jelleines: A family of antimicrobial peptides from the Royal Jelly of honeybees (Apis mellifera). Peptides 2004, 25, 919–928. [Google Scholar] [CrossRef]
  30. Jia, F.; Zhang, Y.; Wang, J.; Peng, J.; Zhao, P.; Zhang, L.; Yao, H.; Ni, J.; Wang, K. The effect of halogenation on the antimicrobial activity, antibiofilm activity, cytotoxicity and proteolytic stability of the antimicrobial peptide Jelleine-I. Peptides 2019, 112, 56–66. [Google Scholar] [CrossRef]
  31. Bahar, A.A.; Ren, D. Antimicrobial peptides. Pharmaceuticals 2013, 6, 1543–1575. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Huang, Y.; Huang, J.; Chen, Y. Alpha-helical cationic antimicrobial peptides: Relationships of structure and function. Protein Cell 2010, 1, 143–152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Srinivasan, S.; Waghu, F.H.; Idicula-Thomas, S.; Venkatesh, K.V. A steady-state modeling approach for simulation of antimicrobial peptide-cell membrane interaction. Biochim. Biophys. Acta Biomembr. 2020, 1862, 183242. [Google Scholar] [CrossRef]
  34. Haake, S.K.; Wang, X. Cloning and expression of FomA, the major outer-membrane protein gene from Fusobacterium nucleatum T18. Arch. Oral Biol. 1997, 42, 19–24. [Google Scholar] [CrossRef] [PubMed]
  35. Cowan, S.W.; Schirmer, T.; Rummel, G.; Steiert, M.; Ghosh, R.; Pauptit, R.A.; Jansonius, J.N.; Rosenbusch, J.P. Crystal structures explain functional properties of two E. coli porins. Nature 1992, 358, 727–733. [Google Scholar] [CrossRef] [PubMed]
  36. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Zidek, A.; Potapenko, A.; et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021, 596, 583–589. [Google Scholar] [CrossRef] [PubMed]
  37. Arthur, J.C.; Gharaibeh, R.Z.; Mühlbauer, M.; Perez-Chanona, E.; Uronis, J.M.; McCafferty, J.; Fodor, A.A.; Jobin, C. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat. Commun. 2014, 5, 4724. [Google Scholar] [CrossRef] [Green Version]
  38. Ray, A.L.; Berggren, K.L.; Restrepo Cruz, S.; Gan, G.N.; Beswick, E.J. Inhibition of MK2 suppresses IL-1β, IL-6, and TNF-α-dependent colorectal cancer growth. Int. J. Cancer 2018, 142, 1702–1711. [Google Scholar] [CrossRef] [Green Version]
  39. Wang, Z.; Li, R.; Tan, J.; Peng, L.; Wang, P.; Liu, J.; Xiong, H.; Jiang, B.; Chen, Y. Syndecan-1 Acts in Synergy with Tight Junction Through Stat3 Signaling to Maintain Intestinal Mucosal Barrier and Prevent Bacterial Translocation. Inflamm. Bowel Dis. 2015, 21, 1894–1907. [Google Scholar] [CrossRef]
  40. Cho, Y.H.; Ro, E.J.; Yoon, J.S.; Mizutani, T.; Kang, D.W.; Park, J.C.; Il Kim, T.; Clevers, H.; Choi, K.Y. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/beta-catenin pathway activation. Nat. Commun. 2020, 11, 5321. [Google Scholar] [CrossRef]
  41. Yu, T.; Guo, F.; Yu, Y.; Sun, T.; Ma, D.; Han, J.; Qian, Y.; Kryczek, I.; Sun, D.; Nagarsheth, N.; et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell 2017, 170, 548–563.e16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Zhang, S.; Cai, S.; Ma, Y. Association between Fusobacterium nucleatum and colorectal cancer: Progress and future directions. J. Cancer 2018, 9, 1652–1659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Tew, G.N.; Clements, D.; Tang, H.; Arnt, L.; Scott, R.W. Antimicrobial activity of an abiotic host defense peptide mimic. Biochim. Biophys. Acta 2006, 1758, 1387–1392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Tanhaeian, A.; Jaafari, M.R.; Ahmadi, F.S.; Vakili-Ghartavol, R.; Sekhavati, M.H. Secretory Expression of a Chimeric Peptide in Lactococcus lactis: Assessment of its Cytotoxic Activity and a Deep View on Its Interaction with Cell-Surface Glycosaminoglycans by Molecular Modeling. Probiotics Antimicrob. Proteins 2019, 11, 1034–1041. [Google Scholar] [CrossRef] [PubMed]
  45. He, F.; Antonucci, L.; Karin, M. NRF2 as a regulator of cell metabolism and inflammation in cancer. Carcinogenesis 2020, 41, 405–416. [Google Scholar] [CrossRef]
  46. He, F.; Ru, X.; Wen, T. NRF2, a Transcription Factor for Stress Response and Beyond. Int. J. Mol. Sci. 2020, 21, 4777. [Google Scholar] [CrossRef]
  47. Sethy, C.; Kundu, C.N. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed. Pharmacother. 2021, 137, 111285. [Google Scholar] [CrossRef]
  48. Fields, G.B.; Noble, R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 1990, 35, 161–214. [Google Scholar] [CrossRef]
  49. Jia, F.; Liang, X.; Wang, J.; Zhang, L.; Zhou, J.; He, Y.; Zhang, F.; Yan, W.; Wang, K. Tryptic Stability and Antimicrobial Activity of the Derivatives of Polybia-CP with Fine-Tuning Modification in the Side Chain of Lysine. Int. J. Pept. Res. Ther. 2021, 27, 851–862. [Google Scholar] [CrossRef]
  50. Chacko, S.; Samanta, S. Novel Thiosemicarbazide Hybrids with Amino Acids and Peptides Against Hepatocellular Carcinoma: A Molecular Designing Approach Towards Multikinase Inhibitor. Curr. Comput. Aided Drug Des. 2015, 11, 279–290. [Google Scholar] [CrossRef]
  51. Ferreira, L.G.; Dos Santos, R.N.; Oliva, G.; Andricopulo, A.D. Molecular docking and structure-based drug design strategies. Molecules 2015, 20, 13384–13421. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Varadi, M.; Anyango, S.; Deshpande, M.; Nair, S.; Natassia, C.; Yordanova, G.; Yuan, D.; Stroe, O.; Wood, G.; Laydon, A.; et al. AlphaFold Protein Structure Database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022, 50, D439–D444. [Google Scholar] [CrossRef] [PubMed]
  53. Zhang, W.; Shi, Y.; Chen, Y.; Yu, S.; Hao, J.; Luo, J.; Sha, X.; Fang, X. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur. J. Pharm. Biopharm. 2010, 75, 341–353. [Google Scholar] [CrossRef] [PubMed]
  54. Cheng, Y.; Wang, G.; Zhao, L.; Dai, S.; Han, J.; Hu, X.; Zhou, C.; Wang, F.; Ma, H.; Li, B.; et al. Periplocymarin Induced Colorectal Cancer Cells Apoptosis Via Impairing PI3K/AKT Pathway. Front. Oncol. 2021, 11, 753598. [Google Scholar] [CrossRef]
  55. Guo, P.; Tian, Z.; Kong, X.; Yang, L.; Shan, X.; Dong, B.; Ding, X.; Jing, X.; Jiang, C.; Jiang, N.; et al. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. J. Exp. Clin. Cancer Res. 2020, 39, 202. [Google Scholar] [CrossRef]
  56. Rubinstein, M.R.; Wang, X.; Liu, W.; Hao, Y.; Cai, G.; Han, Y.W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013, 14, 195–206. [Google Scholar] [CrossRef] [Green Version]
  57. Abed, J.; Emgård, J.E.M.; Zamir, G.; Faroja, M.; Almogy, G.; Grenov, A.; Sol, A.; Naor, R.; Pikarsky, E.; Atlan, K.A.; et al. Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. Cell Host Microbe 2016, 20, 215–225. [Google Scholar] [CrossRef] [Green Version]
  58. He, F.; Antonucci, L.; Yamachika, S.; Zhang, Z.; Taniguchi, K.; Umemura, A.; Hatzivassiliou, G.; Roose-Girma, M.; Reina-Campos, M.; Duran, A.; et al. NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly. J. Hepatol. 2020, 72, 1182–1195. [Google Scholar] [CrossRef] [Green Version]
  59. Yueh, M.F.; He, F.; Chen, C.; Vu, C.; Tripathi, A.; Knight, R.; Karin, M.; Chen, S.; Tukey, R.H. Triclosan leads to dysregulation of the metabolic regulator FGF21 exacerbating high fat diet-induced nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. USA 2020, 117, 31259–31266. [Google Scholar] [CrossRef]
  60. Jin, Z.J. Addition in drug combination (author’s transl). Zhongguo Yao Li Xue Bao 1980, 1, 70–76. [Google Scholar]
  61. Wang, Y.; Yu, H.; Zhang, D.; Wang, G.; Song, W.; Liu, Y.; Ma, S.; Tang, Z.; Liu, Z.; Sakurai, K.; et al. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma. Acta Biomater. 2019, 92, 229–240. [Google Scholar] [CrossRef] [PubMed]
Ijms 24 01469 g001 550
Figure 1. Antimicrobial activities of AMP Jelleine-I (J-I) and its derivatives against Fusobacterium nucleatum (Fn). Effects of Br-J-I (A), Cl-J-I (B), I-J-I (C), J-I (D), and Metronidazole (MET) (E) on the growth of Fn after 24 h treatment of different concentrations of AMPs or positive control MET. Each experiment was repeated at least three times independently. All values are represented as mean ± SEM. **** p < 0.0001, vs. Control.
Figure 1. Antimicrobial activities of AMP Jelleine-I (J-I) and its derivatives against Fusobacterium nucleatum (Fn). Effects of Br-J-I (A), Cl-J-I (B), I-J-I (C), J-I (D), and Metronidazole (MET) (E) on the growth of Fn after 24 h treatment of different concentrations of AMPs or positive control MET. Each experiment was repeated at least three times independently. All values are represented as mean ± SEM. **** p < 0.0001, vs. Control.
Ijms 24 01469 g001
Ijms 24 01469 g002 550
Figure 2. The mechanism of antibacterial activity of Br-J-I. (A) The effect of Br-J-I on the levels of intracellular hydrogen peroxide within Fn. (B) Dose dependent outer membrane permeabilization of Fn by Br-J-I. Time course of fluorescence of NPN bound to inner phospholipid membrane of Fn induced by different concentrations of Br-J-I. (C) Flow cytometry analysis of PI uptake of Fn induced by different concentrations of Br-J-I. (D) Confocal microscopic image of Fn co-stained with AO and FM4-64 with different concentrations of Br-J-I, scale bar: 25 μm. PBS was used as a negative control. (E) Quantitation of FM4-64 fluorescence intensity in C. PBS was used as a negative control. Each experiment was replicated at least three times independently. All values are represented as mean ± SEM. **** p < 0.0001, vs. Fn group.
Figure 2. The mechanism of antibacterial activity of Br-J-I. (A) The effect of Br-J-I on the levels of intracellular hydrogen peroxide within Fn. (B) Dose dependent outer membrane permeabilization of Fn by Br-J-I. Time course of fluorescence of NPN bound to inner phospholipid membrane of Fn induced by different concentrations of Br-J-I. (C) Flow cytometry analysis of PI uptake of Fn induced by different concentrations of Br-J-I. (D) Confocal microscopic image of Fn co-stained with AO and FM4-64 with different concentrations of Br-J-I, scale bar: 25 μm. PBS was used as a negative control. (E) Quantitation of FM4-64 fluorescence intensity in C. PBS was used as a negative control. Each experiment was replicated at least three times independently. All values are represented as mean ± SEM. **** p < 0.0001, vs. Fn group.
Ijms 24 01469 g002
Ijms 24 01469 g003 550
Figure 3. Molecular modeling of Br-J-I binding to potential target FadA. (A) Br-J-I interacts with the tail region of antiparallel α-helices of FadA (PDB: 3ETW) with the three potential hydrogen bonds shown in yellow dashed lines (distance labeled in Å). For clarity, only the protein segments that contain the groups of interest are shown. FadA is shown in an α-carbon rainbow cartoon from blue in N-terminus to Red in C-terminus. The potential interfacial residues for Br-J-I in FadA are shown in lines and Br-J-I are in sticks. N, O, and C atoms of side chains are colored blue, red and gray, respectively. Aromatic ring is in green and Br is in orange. (B) Surface representation of FadA illustrating the Br-J-I binding pocket. Hydrophobic, positively charged, and negatively charged surfaces are colored gray, blue, and red, respectively. Molecular docking was carried out by Vina docking software, and the interactions between ligand and receptor were analyzed and presented by PyMOL.
Figure 3. Molecular modeling of Br-J-I binding to potential target FadA. (A) Br-J-I interacts with the tail region of antiparallel α-helices of FadA (PDB: 3ETW) with the three potential hydrogen bonds shown in yellow dashed lines (distance labeled in Å). For clarity, only the protein segments that contain the groups of interest are shown. FadA is shown in an α-carbon rainbow cartoon from blue in N-terminus to Red in C-terminus. The potential interfacial residues for Br-J-I in FadA are shown in lines and Br-J-I are in sticks. N, O, and C atoms of side chains are colored blue, red and gray, respectively. Aromatic ring is in green and Br is in orange. (B) Surface representation of FadA illustrating the Br-J-I binding pocket. Hydrophobic, positively charged, and negatively charged surfaces are colored gray, blue, and red, respectively. Molecular docking was carried out by Vina docking software, and the interactions between ligand and receptor were analyzed and presented by PyMOL.
Ijms 24 01469 g003
Ijms 24 01469 g004 550
Figure 4. Cell viability of various CRC cell lines and colon epithelial cells in the presence of Br-J-I. Cell viability of human colon cancer cells HCT116 (A), LoVo (B), HT29 (C), murine colon cancer cells MC38 (D), and human colon epithelial cells NCM460 (E) treated with different concentrations of Br-J-I for 72 h.
Figure 4. Cell viability of various CRC cell lines and colon epithelial cells in the presence of Br-J-I. Cell viability of human colon cancer cells HCT116 (A), LoVo (B), HT29 (C), murine colon cancer cells MC38 (D), and human colon epithelial cells NCM460 (E) treated with different concentrations of Br-J-I for 72 h.
Ijms 24 01469 g004
Ijms 24 01469 g005 550
Figure 5. Effects of Br-J-I on the proliferation of human colon cancer cells co-cultured with Fn. Cell number analysis of human colon cancer cells HCT116 co-cultured with or without Fn in the presence of different concentrations of Br-J-I (0, 2.5, 5, and 10 μM) at 24 h (A), 48 h (B), and 72 h (C) to determine cell proliferation. Each experiment was independently performed three times. All data were shown as mean ± SEM. *** p < 0.001, **** p < 0.0001, vs. Fn group. #### p < 0.0001, vs. Control.
Figure 5. Effects of Br-J-I on the proliferation of human colon cancer cells co-cultured with Fn. Cell number analysis of human colon cancer cells HCT116 co-cultured with or without Fn in the presence of different concentrations of Br-J-I (0, 2.5, 5, and 10 μM) at 24 h (A), 48 h (B), and 72 h (C) to determine cell proliferation. Each experiment was independently performed three times. All data were shown as mean ± SEM. *** p < 0.001, **** p < 0.0001, vs. Fn group. #### p < 0.0001, vs. Control.
Ijms 24 01469 g005
Ijms 24 01469 g006 550
Figure 6. Effect of Br-J-I on the growth of the HCT116-xenograft tumors with intratumoral Fn colonization. Tumor volume (A) and tumor weight (B) of HCT116-derived tumors from the CRC mice inoculated with Fn in the presence of Br-J-I (10 mg/kg) or MET (40 mg/kg). (C) Immunohistochemistry of Ki-67+ cancer cells in the HCT116-tumor xenografts after the treatments of Br-J-I (10 mg/kg) and MET (40 mg/kg), respectively. Scale bar: 100 μm (Top), 4-fold magnification of top (Bottom). (D) Quantification of Fn-specific RNA in the tumors of CRC mice with or without Fn colonization in the presence of Br-J-I (10 mg/kg) and MET (40 mg/kg), respectively. (E) QPCR of FadA RNA in tumors of mice engrafted with HCT116 cells with Fn colonization and Br-J-I treatment. All values are represented as mean ± SEM. * p < 0.05, *** p < 0.001, vs. Fn group. ### p < 0.001, #### p < 0.0001, vs. Control.
Figure 6. Effect of Br-J-I on the growth of the HCT116-xenograft tumors with intratumoral Fn colonization. Tumor volume (A) and tumor weight (B) of HCT116-derived tumors from the CRC mice inoculated with Fn in the presence of Br-J-I (10 mg/kg) or MET (40 mg/kg). (C) Immunohistochemistry of Ki-67+ cancer cells in the HCT116-tumor xenografts after the treatments of Br-J-I (10 mg/kg) and MET (40 mg/kg), respectively. Scale bar: 100 μm (Top), 4-fold magnification of top (Bottom). (D) Quantification of Fn-specific RNA in the tumors of CRC mice with or without Fn colonization in the presence of Br-J-I (10 mg/kg) and MET (40 mg/kg), respectively. (E) QPCR of FadA RNA in tumors of mice engrafted with HCT116 cells with Fn colonization and Br-J-I treatment. All values are represented as mean ± SEM. * p < 0.05, *** p < 0.001, vs. Fn group. ### p < 0.001, #### p < 0.0001, vs. Control.
Ijms 24 01469 g006
Ijms 24 01469 g007 550
Figure 7. Effect of Br-J-I on the Fn-induced inflammation in vivo. (A) H&E staining of colon tissues of HCT116-xenograft-bearing mice to examine the gut inflammation and barrier. Scale bar: 100 μM (Top), 4-fold magnification of top (Bottom). (B–E) Quantification of the expression of genes encoding the proinflammatory cytokines TNF-α (B,D) and IL-1β (C,E) in the tumors (B,C) and the colon tissues (D,E) of the CRC cells-engrafted mice with or without Fn colonization in the presence of Br-J-I (10 mg/kg) and MET (40 mg/kg). All values are represented as mean ± SEM. * p < 0.05, ** p < 0.01, **** p < 0.0001, vs. Fn group. ## p < 0.01, #### p < 0.0001, vs. Control.
Figure 7. Effect of Br-J-I on the Fn-induced inflammation in vivo. (A) H&E staining of colon tissues of HCT116-xenograft-bearing mice to examine the gut inflammation and barrier. Scale bar: 100 μM (Top), 4-fold magnification of top (Bottom). (B–E) Quantification of the expression of genes encoding the proinflammatory cytokines TNF-α (B,D) and IL-1β (C,E) in the tumors (B,C) and the colon tissues (D,E) of the CRC cells-engrafted mice with or without Fn colonization in the presence of Br-J-I (10 mg/kg) and MET (40 mg/kg). All values are represented as mean ± SEM. * p < 0.05, ** p < 0.01, **** p < 0.0001, vs. Fn group. ## p < 0.01, #### p < 0.0001, vs. Control.
Ijms 24 01469 g007
Ijms 24 01469 g008 550
Figure 8. Effect of Br-J-I on the integrity of intestinal mucosa in murine engrafted with CRC and Fn. (A,B) Quantification of the effect of Br-J-I on the expression of genes encoding the tight junction proteins Claudin (A), and ZO-1 (B) in the colon tissues of the CRC cells-engrafted mice with or without Fn colonization in the presence of Br-J-I (10 mg/kg) and MET (40 mg/kg). Data are expressed as mean ± SEM. * p < 0.05, *** p < 0.001, vs. Fn group. ### p < 0.001, #### p < 0.0001, vs. Control.
Figure 8. Effect of Br-J-I on the integrity of intestinal mucosa in murine engrafted with CRC and Fn. (A,B) Quantification of the effect of Br-J-I on the expression of genes encoding the tight junction proteins Claudin (A), and ZO-1 (B) in the colon tissues of the CRC cells-engrafted mice with or without Fn colonization in the presence of Br-J-I (10 mg/kg) and MET (40 mg/kg). Data are expressed as mean ± SEM. * p < 0.05, *** p < 0.001, vs. Fn group. ### p < 0.001, #### p < 0.0001, vs. Control.
Ijms 24 01469 g008
Ijms 24 01469 g009 550
Figure 9. Br-J-I synergizes with 5-FU to inhibit proliferation of HCT116 cells. The HCT116 cells co-cultured with Fn were treated with 5-FU (5 μM) alone or in combination with different concentrations of B-J-I for 48 h and MTT assay was conducted to determine cell viability. (A) 10 μM B Br-J-I /5 μM 5-FU, (B) 20 μM B Br-J-I /5 μM 5-FU. Results were representative of three independent experiments performed in four replicates and were expressed as mean ± SEM. ** p < 0.01, **** p < 0.0001, vs. Fn group.
Figure 9. Br-J-I synergizes with 5-FU to inhibit proliferation of HCT116 cells. The HCT116 cells co-cultured with Fn were treated with 5-FU (5 μM) alone or in combination with different concentrations of B-J-I for 48 h and MTT assay was conducted to determine cell viability. (A) 10 μM B Br-J-I /5 μM 5-FU, (B) 20 μM B Br-J-I /5 μM 5-FU. Results were representative of three independent experiments performed in four replicates and were expressed as mean ± SEM. ** p < 0.01, **** p < 0.0001, vs. Fn group.
Ijms 24 01469 g009
Table
Table 1. Amino acid sequence of J-I, Br-J-I, Cl-J-I, and I-J-I.
Table 1. Amino acid sequence of J-I, Br-J-I, Cl-J-I, and I-J-I.
NamePeptides Sequence
J-IPFKLSLHL-NH2
Br-J-IPFaKLSLHL-NH2
Cl-J-IPFbKLSLHL-NH2
I-J-IPFcKLSLHL-NH2
a, 4-Br-phe-amino acid; b, 4-Cl-phe-amino acid; and c, 4-I-phe-amino acid.
Table
Table 2. MIC and MBC of peptides against Fn.
Table 2. MIC and MBC of peptides against Fn.
NameBr-J-ICl-J-II-J-IJ-IMET
MIC5 μM10 μM10 μM160 μM0.125 μM
MBC10 μM40 μM20 μM320 μM0.5 μM
MET: Metronidazole.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Jia, F.; Yu, Q.; Wang, R.; Zhao, L.; Yuan, F.; Guo, H.; Shen, Y.; He, F. Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression. Int. J. Mol. Sci. 2023, 24, 1469. https://doi.org/10.3390/ijms24021469

AMA Style

Jia F, Yu Q, Wang R, Zhao L, Yuan F, Guo H, Shen Y, He F. Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression. International Journal of Molecular Sciences. 2023; 24(2):1469. https://doi.org/10.3390/ijms24021469

Chicago/Turabian Style

Jia, Fengjing, Qun Yu, Ruolei Wang, Ling Zhao, Fuwen Yuan, Haidong Guo, Yunhui Shen, and Feng He. 2023. "Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression" International Journal of Molecular Sciences 24, no. 2: 1469. https://doi.org/10.3390/ijms24021469

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop